Kesimpta is an ofatumumab auto-injector therapy for adults with relapsing forms of multiple sclerosis.
Currently Offered
Kesimpta (ofatumumab) is a prescription medicine for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting disease. Patients self-administer the medicine with an auto-injector pen.
In clinical studies, Kesimpta reduced the annual rate of relapses and slowed disability progression compared with teriflunomide. Novartis provides patient support services including co-pay assistance for eligible prescriptions.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
